Neuronetics, Inc. filed a Form 8-K on November 4, 2026, announcing its financial results for the three and nine months ended September 30, 2026, alongside an investor presentation released the same day.

Key Highlights

  • Reporting period covered: Financial results for the three and nine months ended September 30, 2026, according to the filing.
  • Press release attached: A press release dated November 4, 2026, is furnished as Exhibit 99.1 to the filing.
  • Investor presentation filed: A company presentation for November 2026 is attached as Exhibit 99.2 under Regulation FD Disclosure (Item 7.01).
  • Signing officer: The filing was signed by Nir Naor, Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer.
  • Forward-looking caution: The filing states that forward-looking statements "are subject to significant risks and uncertainties and actual results could differ materially from those projected."

Neuronetics Files Q3 2026 Results Disclosure and Investor Presentation

Neuronetics, Inc. (NASDAQ:STIM), a Malvern, Pennsylvania-based medical device company, disclosed its third-quarter financial results through a Form 8-K filed November 4, 2026, with the U.S. Securities and Exchange Commission. According to the filing, the company issued a press release on that date covering results for both the three and nine months ended September 30, 2026, which is furnished as Exhibit 99.1. The filing notes that the press release is incorporated by reference into Item 2.02.

Separately, the company disclosed under Item 7.01 (Regulation FD) that it released a presentation on November 4, 2026, described as one "it may present to certain investors." That presentation, labeled "Company Presentation November 2026," is attached as Exhibit 99.2. The filing specifies that neither Exhibit 99.1 nor Exhibit 99.2 shall be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other company filings with the SEC unless expressly stated.

The filing contains forward-looking statements, which the company identifies as subject to its cautionary language under the Private Securities Litigation Reform Act of 1995. Among the risk factors cited are the company's "ability to continue as a going concern," reliance on the NeuroStar Advanced Therapy System for revenues, reimbursement availability from third-party payors, and the effects of its prior transaction with Greenbrook TMS Inc. The company states it undertakes "no duty or obligation to update any forward-looking statements" except as required by law.

What Was Disclosed

Neuronetics filed an 8-K on November 4, 2026, furnishing a press release with Q3 2026 financial results and an investor presentation, both dated the same day, signed by CFO Nir Naor.